COMMUNIQUÉS West-GlobeNewswire

Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
07/11/2025
PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
07/11/2025
S ingle ascending dose data readout for VTP-1000 expected before the end of 2 025 Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026 Proposed combination [...]
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
07/11/2025
-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial- [...]
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
07/11/2025
CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 [...]
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
07/11/2025
PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies [...]
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
07/11/2025
Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both Bria-BRES+™ ( [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
07/11/2025
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
07/11/2025
– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE [...]
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
07/11/2025
BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today [...]
Vor Bio to Participate in Upcoming Investor Conferences
07/11/2025
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following [...]
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
07/11/2025
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and older compared [...]
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
07/11/2025
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash [...]
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
07/11/2025
The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS (Vafidemstat) Received feedback from the FDA [...]
Vaxart to Host Upcoming Conference Calls
07/11/2025
Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
07/11/2025
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant [...]
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
07/11/2025
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Dr. Adrian Bot, a renowned biopharmaceutical founder and scientist, has joined [...]
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...
07/11/2025
ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la [...]
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
07/11/2025
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be [...]

Pages